riociguat
AssetAlso BAY 63-2521, Adempas
Soluble guanylate cyclase stimulator enhancing cGMP production to cause vasodilation.
- Stage
- Approved
- Modality
- Small molecule
- Target
- GUCY1A1
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Chronic thromboembolic pulmonary hypertension
Approved, prnewswire.com, 5 Oct 2026
Pulmonary arterial hypertension
Approved, prnewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Evidence for its targets2
- Competitors7
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.